Mga Batayang Estadistika
| LEI | 529900PYI5BSGQNATP82 |
| CIK | 1367920 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Concert Pharmaceuticals Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36310 Concert Pharmaceuticals, Inc. (Exact name of registrant as specifi |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-195125 No. 333-202453 No. 333-209841 No. 333-216459 No. 333-223335 No. 333-229932 No. 333-236679 No. 333-253481 No. 333-263246 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-195125 Post-Effective Amendment No. 1 to |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-195125 No. 333-202453 No. 333-209841 No. 333-216459 No. 333-223335 No. 333-229932 No. 333-236679 No. 333-253481 No. 333-263246 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-195125 Post-Effective Amendment No. 1 to FORM S-8 |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-195125 No. 333-202453 No. 333-209841 No. 333-216459 No. 333-223335 No. 333-229932 No. 333-236679 No. 333-253481 No. 333-263246 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-195125 Post-Effective Amendment No. 1 to |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-195125 No. 333-202453 No. 333-209841 No. 333-216459 No. 333-223335 No. 333-229932 No. 333-236679 No. 333-253481 No. 333-263246 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-195125 Post-Effective Amendment No. 1 to FORM S-8 |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-195125 No. 333-202453 No. 333-209841 No. 333-216459 No. 333-223335 No. 333-229932 No. 333-236679 No. 333-253481 No. 333-263246 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-195125 Post-Effective Amendment No. 1 to FORM S-8 |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-195125 No. 333-202453 No. 333-209841 No. 333-216459 No. 333-223335 No. 333-229932 No. 333-236679 No. 333-253481 No. 333-263246 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-195125 Post-Effective Amendment No. 1 to FORM S-8 |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 POS AM As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-202451 No. 333-223334 No. 333-249862 No. 333-263247 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-202451 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-223334 Post-Effective Amendment No. |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-202451 No. 333-223334 No. 333-249862 No. 333-263247 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-202451 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-223334 Post-Effective Amendment No. 1 to FO |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-195125 No. 333-202453 No. 333-209841 No. 333-216459 No. 333-223335 No. 333-229932 No. 333-236679 No. 333-253481 No. 333-263246 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-195125 Post-Effective Amendment No. 1 to FORM S-8 |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-195125 No. 333-202453 No. 333-209841 No. 333-216459 No. 333-223335 No. 333-229932 No. 333-236679 No. 333-253481 No. 333-263246 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-195125 Post-Effective Amendment No. 1 to FORM S-8 |
|
| March 6, 2023 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Concert Pharmaceuticals, Inc. (Name of Subject Company) Concert Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title o |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-195125 No. 333-202453 No. 333-209841 No. 333-216459 No. 333-223335 No. 333-229932 No. 333-236679 No. 333-253481 No. 333-263246 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-195125 Post-Effective Amendment No. 1 to FORM S-8 |
|
| March 6, 2023 |
Sun Pharma Completes Acquisition of Concert Pharmaceuticals EX-99.a(5)(r) Exhibit (a)(5)(R) Sun Pharma Completes Acquisition of Concert Pharmaceuticals • Acquisition Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, to Sun Pharma’s Global Dermatology Portfolio MUMBAI, India and PRINCETON, N.J., March 6, 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BS |
|
| March 6, 2023 |
BYLAWS CONCERT PHARMACEUTICALS, INC. * * * * * ARTICLE 1 EX-3.1 Exhibit 3.1 BYLAWS OF CONCERT PHARMACEUTICALS, INC. * * * * * ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors ma |
|
| March 6, 2023 |
CONTINGENT VALUE RIGHTS AGREEMENT EX-2.2 Exhibit 2.2 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of March 6, 2023 (this “Agreement”), is entered into by and between Sun Pharmaceutical Holdings USA, Inc., a Delaware corporation (“SPH”), Sun Pharmaceutical Industries Ltd., an entity organized under the laws of India (“SPIL” and, together with SPH, “Parent”), and Computershare Inc., a Delaware c |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 POS AM As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-202451 No. 333-223334 No. 333-249862 No. 333-263247 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-202451 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-223334 Post-Effective Amendment No. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Commis |
|
| March 6, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) CONCERT PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) FOLIAGE MERGER SUB, INC. a wholly owned indirect subsidiary of SUN PHARMACEUTICAL INDUSTRIES LTD. (Names of Filing Persons (Of |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 POS AM As filed with the Securities and Exchange Commission on March 6, 2023 No. 333-202451 No. 333-223334 No. 333-249862 No. 333-263247 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-202451 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-223334 Post-Effective Amendment No. |
|
| March 6, 2023 |
Sun Pharma Completes Acquisition of Concert Pharmaceuticals EX-99.A5I Exhibit (a)(5)(I) Sun Pharma Completes Acquisition of Concert Pharmaceuticals • Acquisition Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, to Sun Pharma’s Global Dermatology Portfolio MUMBAI, India and PRINCETON, N.J., March 6, 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 5 |
|
| February 24, 2023 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Concert Pharmaceuticals, Inc. (Name of Subject Company) Concert Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title o |
|
| February 24, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) CONCERT PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) FOLIAGE MERGER SUB, INC. a wholly owned indirect subsidiary of SUN PHARMACEUTICAL INDUSTRIES LTD. (Names of Filing Persons (Of |
|
| February 14, 2023 |
EX-99.1 2 d444387dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2023 |
CNCE / Concert Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d33sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* CONCERT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 206022105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Sta |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022105 (CUSIP Nu |
|
| February 14, 2023 |
CNCE / Concert Pharmaceuticals Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d444387dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022 105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this State |
|
| February 10, 2023 |
SC 13G 1 cnce21023.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CONCERT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 206022105 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CONCERT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 206022105 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 2, 2023 |
EX-99.(a)(1)(e) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated February 2, 2023, and the related Letter of Transmittal, and any amendments or supplements to such Offer to Purchase or Letter of Transmittal. Purchaser (as defined |
|
| February 2, 2023 |
EX-99.(a)(1)(c) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of CONCERT PHARMACEUTICALS, INC. at $8.00 per share, in cash, plus one non-transferable contingent value right per share, which represents the right to receive contingent payments of up to $3.50 per share, in cash, in the aggregate, upon the achievement of specified milestones, pursuant to the Offer to Purch |
|
| February 2, 2023 |
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT EX-99.(d)(2) Exhibit (d)(2) FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], 2023 (this “Agreement”), is entered into by and between Sun Pharmaceutical Industries Ltd., an entity organized under the laws of India (“Parent”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a fede |
|
| February 2, 2023 |
Concert Pharmaceuticals, Inc. 65 Hayden Avenue, Suite 3000N Lexington, MA 02421 EX-99.(d)(4) Exhibit (d)(4) CONFIDENTIAL Concert Pharmaceuticals, Inc. 65 Hayden Avenue, Suite 3000N Lexington, MA 02421 December 13, 2022 Sun Pharmaceutical Industries Ltd. Sun House, 201 B/1 Western Express Highway Goregaon (E), Mumbai – 400063, India Confidentiality Agreement In connection with your consideration of a possible negotiated business combination transaction between Concert Pharmace |
|
| February 2, 2023 |
EX-99.(d)(6) Exhibit (d)(6) January 17, 2023 Concert Pharmaceuticals, Inc. 65 Hayden Avenue, Suite 3000N Lexington, MA 02421 Re: Exclusivity Extension To whom it may concern: Reference is hereby made to that certain letter agreement (the “Exclusivity Agreement”) dated as of December 16, 2022, by and between Concert Pharmaceuticals, Inc. (the “Company”) and Sun Pharmaceutical Industries Limited (“S |
|
| February 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Concert Pharmaceuticals, Inc. (Name of Subject Company) Concert Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of |
|
| February 2, 2023 |
EX-99.(d)(5) Exhibit (d)(5) STRICTLY CONFIDENTIAL PRIVATE AND CONFIDENTIAL December 16, 2022 Sun Pharmaceutical Industries Limited SUN HOUSE, 201 B/1 Western Express Highway Goregaon (E) Mumbai 400063 This letter agreement (this “Agreement”) is entered into between Concert Pharmaceuticals, Inc. (the “Company”) and Sun Pharmaceutical Industries Limited (“Sun Pharma”) in connection with a possible n |
|
| February 2, 2023 |
CONFIDENTIAL DISCLOSURE AGREEMENT SUN PHARMACEUTICAL INDUSTRIES LTD. CONCERT PHARMACEUTICALS, INC. EX-99.(d)(3) Exhibit (d)(3) Confidential & Privileged CONFIDENTIAL DISCLOSURE AGREEMENT BETWEEN SUN PHARMACEUTICAL INDUSTRIES LTD. AND CONCERT PHARMACEUTICALS, INC. Page 1 of 6 Confidential & Privileged CONFIDENTIAL DISCLOSURE AGREEMENT This Confidential Disclosure Agreement (the “Agreement”) is entered into as of the latest dated signature below (the “Effective Date”) by and between Sun Pharmaceu |
|
| February 2, 2023 |
EX-FILING FEES 12 d419157dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Concert Pharmaceuticals, Inc. (Name of Subject Company - Issuer) Foliage Merger Sub, Inc. (Names of Filing Persons - Offeror) Sun Pharmaceutical Industries Ltd. (Names of Filing Persons - Parent of Offeror) Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount o |
|
| February 2, 2023 |
EX-99.(a)(1)(a) Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of CONCERT PHARMACEUTICALS, INC. at $8.00 per share, in cash, plus one non-tradeable contingent value right per share, which represents the right to receive contingent payments of up to $3.50 per share, in cash, in the aggregate, upon the achievement of specified milestones, by FOLIAGE MERG |
|
| February 2, 2023 |
EX-99.(a)(1)(d) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of CONCERT PHARMACEUTICALS, INC. at $8.00 per share, in cash, plus one non-transferable contingent value right per share, which represents the right to receive contingent payments of up to $3.50 per share, in cash, in the aggregate, upon the achievement of specified milestones, pursuant to the Offer to Purch |
|
| February 2, 2023 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CONCERT PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) FOLIAGE MERGER SUB, INC. a wholly owned indirect subsidiary of SUN PHARMACEUTICAL INDUSTRIES LTD. (Names of Filing Persons (Offeror)) Common Stock |
|
| February 2, 2023 |
EX-99.(a)(1)(b) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of CONCERT PHARMACEUTICALS, INC. at $8.00 per share, in cash, plus one non-transferable contingent value right per share, which represents the right to receive contingent payments of up to $3.50 per share, in cash, in the aggregate, upon the achievement of specified milestones, pursuant to the Offer to Purchas |
|
| February 1, 2023 |
Exhibit 99.1 Sun Pharma Q3 FY23 Earnings Call Transcript 06:30 pm January 31, 2023 Corporate Participants Dilip Shanghvi Managing Director, Sun Pharmaceutical Industries Ltd. Abhay Gandhi CEO (North America Business), Sun Pharmaceutical Industries Ltd. C. S. Muralidharan Chief Financial Officer, Sun Pharmaceutical Industries Ltd. Kirti Ganorkar CEO (India Business), Sun Pharmaceutical Industries L |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CONCERT PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) FOLIAGE MERGER SUB, INC. a wholly owned subsidiary of SUN PHARMACEUTICAL INDUSTRIES LTD. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.00 |
|
| January 31, 2023 |
Exhibit 99.1 The following are excerpts from a press release disseminated by Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) and published on its website on January 31, 2023 discussing Sun Pharma’s Q3FY23 earnings results: “Dilip Shanghvi, Managing Director of the Company said, “Specialty is expected to continue as a key growth driver for Sun. We are investing to scale up this business, especial |
|
| January 31, 2023 |
SC TO-C 1 d453138dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CONCERT PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) FOLIAGE MERGER SUB, INC. a wholly owned subsidiary of SUN PHARMACEUTICAL INDUSTRIES LTD. (Names of Filing Persons (Off |
|
| January 31, 2023 |
Exhibit 99.2 The following information was provided by Sun Pharmaceutical Industries Ltd. as a note to its Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended December 31, 2022, which document was published on its website on January 31, 2023: “On January 19, 2023, the Company has executed a definitive agreement under which it will acquire all outstanding sha |
|
| January 19, 2023 |
Exhibit 99.3 On January 19, 2023, Concert Pharmaceuticals, Inc. (“Concert”) made the following announcement via Twitter regarding the planned tender offer by Foliage Merger Sub, Inc. (“Purchaser”), a Delaware corporation and a wholly owned indirect subsidiary of Sun Pharmaceutical Industries Ltd. (“Parent”), to acquire all of the issued and outstanding shares of the common stock of Concert, to be |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CONCERT PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) FOLIAGE MERGER SUB, INC. a wholly owned subsidiary of SUN PHARMACEUTICAL INDUSTRIES LTD. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.00 |
|
| January 19, 2023 |
Exhibit 99.1 Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma’s Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma’s |
|
| January 19, 2023 |
EX-99.1 Exhibit 99.1 Page 1 of 6 Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverage Sun Pharma’s global infrastructure to provide broad access to deuruxolitnib for Patients with Alopecia Areata Strengt |
|
| January 19, 2023 |
EX-2.1 2 d433505dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG SUN PHARMACEUTICAL INDUSTRIES LTD., FOLIAGE MERGER SUB, INC. and CONCERT PHARMACEUTICALS, INC. Dated as of January 19, 2023 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 Section 1.1. Definitions 2 ARTICLE 2 THE OFFER 17 Section 2.1. Tender Offer 17 Section 2.2. Actions of Parent and Merger Sub 20 S |
|
| January 19, 2023 |
SC14D9C 1 d450712dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Concert Pharmaceuticals, Inc. (Name of Subject Company) Concert Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Cla |
|
| January 19, 2023 |
Exhibit 99.4 On January 19, 2023, Concert Pharmaceuticals, Inc. (“Concert”) made the following announcement via Instagram regarding the planned tender offer by Foliage Merger Sub, Inc. (“Purchaser”), a Delaware corporation and a wholly owned indirect subsidiary of Sun Pharmaceutical Industries Ltd. (“Parent”), to acquire all of the issued and outstanding shares of the common stock of Concert, to b |
|
| January 19, 2023 |
Exhibit 99.2 On January 19, 2023, Concert Pharmaceuticals, Inc. (“Concert”) made the following announcement via LinkedIn regarding the planned tender offer by Foliage Merger Sub, Inc. (“Purchaser”), a Delaware corporation and a wholly owned indirect subsidiary of Sun Pharmaceutical Industries Ltd. (“Parent”), to acquire all of the issued and outstanding shares of the common stock of Concert, to be |
|
| January 19, 2023 |
EMPLOYEE FAQS: SUN PHARMA-CONCERT MERGER AGREEMENT January 19, 2023 Exhibit 99.1 EMPLOYEE FAQS: SUN PHARMA-CONCERT MERGER AGREEMENT January 19, 2023 This document is intended to provide answers to many of the questions you may have about the proposed merger between Sun Pharma and Concert. Today’s announcement is just the first step in the process. While we may not have all the answers immediately, we are committed to being as transparent and timely as possible in |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Concert Pharmaceuticals, Inc. (Name of Subject Company) Concert Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 206 |
|
| January 19, 2023 |
Concert Transaction Strategic Partner Email Exhibit 99.5 Concert Transaction Strategic Partner Email Dear [Valued Partner], Today we announced some important news about Concert Pharmaceuticals – we’ve agreed to be acquired by Sun Pharma, a global leader in the development and commercialization of high-quality, affordable medicines with an international, autoimmune dermatology-focused sales force. Sun Pharma has U.S. operations headquartered |
|
| January 19, 2023 |
Exhibit 99.8 EMPLOYEE COMMUNICATION Subject: Important Concert News Today Team, This morning we announced that Sun Pharma will acquire Concert, gaining full ownership of the Company and deuruxolitinib. Through this transaction, we will establish a strong path for the future of deuruxolitinib – enabling the valuable drug candidate we have all worked so tirelessly to develop to reach the market effe |
|
| January 19, 2023 |
Concert Transaction IR Courtesy Email Exhibit 99.6 Concert Transaction IR Courtesy Email Subject: Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata [Dear NAME // Hello], I’m reaching out to make sure you saw the exciting news – Concert has agreed to be acquired by Sun Pharma, a leading global branded and generics company, through a tender offer for an upfront payment of $8.00 per share |
|
| January 19, 2023 |
Sun Pharma Facebook Post (Sun Pharmaceutical Industries Limited), January 19, 2023 Exhibit 99.4 Sun Pharma Facebook Post (Sun Pharmaceutical Industries Limited), January 19, 2023 The following Facebook post was made by Sun Pharma on January 19, 2023: Sun Pharma Sun Pharmaceutical Industries Limited 40m We are excited to announce that Sun Pharma has entered into a definitive agreement to acquire Concert Pharmaceuticals, Inc. This acquisition adds to our global dermatology pipelin |
|
| January 19, 2023 |
Sun Pharma Tweet (@SunPharma_Live), January 19, 2023 Exhibit 99.3 Sun Pharma Tweet (@SunPharmaLive), January 19, 2023 The following tweet was posted by Sun Pharma on January 19, 2023: Sun Pharma Sun Pharma @SunPharmaLive Sun Pharma announces signing of definitive agreement to acquire Concert Pharmaceuticals, Inc., adding a late-stage potential best-in-class treatment for patients with Alopecia Areata. Learn more: bit.ly/3QRWMNZ Sun Pharma "Sun Pharm |
|
| January 19, 2023 |
Sun Pharma Tweet (@SunPharma_US), January 19, 2023 Exhibit 99.2 Sun Pharma Tweet (@SunPharmaUS), January 19, 2023 The following tweet was posted by Sun Pharma on January 19, 2023: Sun Pharma Sun Pharma US @SunPharma US Sun Pharma announces signing of definitive agreement to acquire Concert Pharmaceuticals, Inc., adding a late-stage potential best-in-class treatment for patients with Alopecia Areata. Learn more: bit.ly/3weSeb3 Sun Pharma "Sun Pharm |
|
| January 19, 2023 |
Concert Transaction KOLs / Patient Advocacy Groups / Trial Sites / CROs and Consultants Email EX-99.7 8 d453799dex997.htm EX-99.7 Exhibit 99.7 Concert Transaction KOLs / Patient Advocacy Groups / Trial Sites / CROs and Consultants Email Dear [Dr. [NAME] / Valued Partner / INSERT CUSTOMARY GREETING], Today we announced some important news about Concert Pharmaceuticals – we’ve agreed to be acquired by Sun Pharma, a global leader in the development and commercialization of high-quality, affor |
|
| January 19, 2023 |
Sun Pharma LinkedIn Post (SUN PHARMA), January 19, 2023 EX-99.5 6 dp187242ex9905.htm EXHIBIT 99.5 Exhibit 99.5 Sun Pharma LinkedIn Post (SUN PHARMA), January 19, 2023 The following LinkedIn post was made by Sun Pharma on January 19, 2023: Sun Pharma SUN PHARMA 1,004,940 followers 47m We are excited to announce that Sun Pharma has entered into a definitive agreement to acquire Concert Pharmaceuticals, Inc. This acquisition adds to our global dermatology |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Com |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Com |
|
| November 7, 2022 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results Company Plans to Submit NDA in First Half of 2023 for Deuruxoliti |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCER |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Comm |
|
| August 4, 2022 |
Creating New Possibilities for Patients to Live Their Lives August 2022 ? 2022 Concert Pharmaceuticals, Inc. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCERT PHA |
|
| August 4, 2022 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results CTP-543 Positive Topline Results Reported in THRIVE-AA1 and THRI |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Commi |
|
| August 4, 2022 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF CONCERT PHARMACEUTICALS, INC. (originally incorporated on April 12, 2006) Concert Pharmaceuticals, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Law (the ?DGCL?), does hereby certify as follows: A. The current name of the Corporation is Concert Pharmaceuti |
|
| June 13, 2022 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Commiss |
|
| June 3, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 3, 2022 |
10,000,000 Shares CONCERT PHARMACEUTICALS, INC. Common Stock 424B5 1 d355977d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-249862 PROSPECTUS SUPPLEMENT (to Prospectus dated November 16, 2020) 10,000,000 Shares CONCERT PHARMACEUTICALS, INC. Common Stock We are offering 10,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “CNCE.” On June 1, 2022, the last sale |
|
| June 3, 2022 |
Exhibit 1.1 Execution Version 10,000,000 Shares Concert Pharmaceuticals, Inc. UNDERWRITING AGREEMENT June 1, 2022 JEFFERIES LLC TRUIST SECURITIES, INC. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o TRUIST SECURITIES, INC. 3333 Peachtree Road, NE Atlanta, Georgia 30326 Ladies and Gentlemen: Introductory. Concert Pharmaceuticals, Inc |
|
| June 3, 2022 |
Exhibit 99.1 For additional information contact: Justine E. Koenigsberg (Investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Announces Pricing of Public Offering Lexington, MA (June 1, 2022) ? Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today a |
|
| June 3, 2022 |
Form of Warrant Amendment Agreement Exhibit 4.1 [], 2022 [Holder] [Address] Re: Amendment to Tranche 1 Warrants Dear Holders: Reference is hereby made to a proposed offering by Concert Pharmaceuticals, Inc. (the ?Company?) of shares of its common stock, par value $0.001 per share (?Common Stock?), to be consummated on or before June 15, 2022 (the ?Offering?). This letter confirms that the undersigned fund[s] (i) [has][have collectiv |
|
| May 31, 2022 |
10,000,000 Shares CONCERT PHARMACEUTICALS, INC. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-249862 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| May 23, 2022 |
Exhibit 99.1 Creating New Possibilities for Patients to Live Their Lives May 2022 ? 2022 Concert Pharmaceuticals, Inc. All Rights Reserved. Forward-Looking Statements Any statements in this presentation about our future expectations, plans and prospects, including, among others, statements about our expectations regarding the development of CTP-543, the potential for CTP-543 to be a best-in-class |
|
| May 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Commiss |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCERT PH |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Commissi |
|
| May 5, 2022 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine E. Koenigsberg (Investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports First Quarter 2022 Financial Results Phase 3 Data Readout in Alopecia Areata Expected Second Quarte |
|
| April 26, 2022 |
DEF 14A 1 a2022definitiveproxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only |
|
| April 26, 2022 |
Concert Pharmaceuticals, Inc. 65 Hayden Avenue, Suite 3000N Lexington, MA 02421 CORRESP 1 filename1.htm Concert Pharmaceuticals, Inc. 65 Hayden Avenue, Suite 3000N Lexington, MA 02421 April 26, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Concert Pharmaceuticals, Inc.: Registration Statement on Form S-3 filed March 3, 2022 (File No. 333-263247) Ladies and Gentlemen: P |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 14, 2022 |
PRE 14A 1 a2022proxy.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ý Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permi |
|
| March 3, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Concert Pharmaceuticals, Inc. |
|
| March 3, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Concert Pharmaceuticals, Inc. |
|
| March 3, 2022 |
Exhibit 4.5 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Concert Pharmaceuticals, Inc. (?us,? ?our? or ?we?) is a summary of the rights of our common stock, our Series X1 preferred stock, warrants to purchase Series X1 preferred stock and certain provisions of our restated certificate of incorporation and our amended and restated by-laws currently in effect. This |
|
| March 3, 2022 |
Summary of Non-Employee Director Compensation Program Exhibit 10.12 Summary of Non-Employee Director Compensation Program The Board of Directors (the ?Board?) of Concert Pharmaceuticals, Inc. (the ?Company?) has approved the following non-employee director compensation program. Each non-employee director will receive a cash retainer for service on the Board and for service on each committee of which the director is a member. The Chairman of the Board |
|
| March 3, 2022 |
Exhibit 4.2 CONCERT PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04 (c) 312(c) 4.04 (c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 3 |
|
| March 3, 2022 |
Form of Subordinated Indenture Exhibit 4.3 CONCERT PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES 1 CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) |
|
| March 3, 2022 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update Two Phase 3 Registrational Clinical Trials Fully En |
|
| March 3, 2022 |
Royalty Purchase Agreement, dated as of November 3, 2021, by and among the Registrant and the Buyers Exhibit 10.18 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Execution Version ROYALTY PURCHASE AGREEMENT This Royalty Purchase Agreement is dated as of November 3, 2021 (this ?Agreement? |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Commis |
|
| March 3, 2022 |
Power of Attorney (included on the signature pages of this Registration Statement) As filed with the Securities and Exchange Commission on March 3, 2022 Registration No. |
|
| March 3, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Concert Pharmaceuticals Securities Corp. Massachusetts Concert Pharma U.K. Ltd United Kingdom Concert Pharma Ireland Limited Ireland |
|
| March 3, 2022 |
Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| March 3, 2022 |
As filed with the Securities and Exchange Commission on March 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 3, 2022 Registration No. |
|
| March 3, 2022 |
Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36310 CONCERT PHARMA |
|
| February 14, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 14, 2022 |
CNCE / Concert Pharmaceuticals Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022 105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 14, 2022 |
CNCE / Concert Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. )* CONCERT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Com |
|
| January 13, 2022 |
CNCE / Concert Pharmaceuticals Inc / BANK OF AMERICA CORP /DE/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 02)* CONCERT PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 206022105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| November 15, 2021 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 15, 2021 with respect to the shares of Common Stock, $0.001 par value per share of Concert Pharmaceuticals, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and |
|
| November 15, 2021 |
CNCE / Concert Pharmaceuticals Inc / BIOTECHNOLOGY VALUE FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022105 (CUSIP Num |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Com |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCER |
|
| November 9, 2021 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update CTP-543 THRIVE-AA1 Phase 3 Trial in P |
|
| November 8, 2021 |
Exhibit 4.1 CONCERT PHARMACEUTICALS, INC. TRANCHE [1][2] WARRANT TO PURCHASE SERIES X1 PREFERRED STOCK Number of Shares: [?][?] (subject to adjustment) Warrant No. [ ] Original Issue Date: November [ ], 2021 Concert Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, |
|
| November 8, 2021 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 3, 2021, between Concert Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, |
|
| November 8, 2021 |
Certificate of Designation of Preferences, Rights and Limitations of Series X1 Preferred Stock Exhibit 3.1 CONCERT PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X1 PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW CONCERT PHARMACEUTICALS, INC., a Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?) does hereby certify th |
|
| November 8, 2021 |
Exhibit 99.1 For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Announces $65 Million Financing Financing Provided by Leading Healthcare Funds BVF Partners L.P. and RA Capital Management |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 5, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-249862 PROSPECTUS SUPPLEMENT (to Prospectus dated November 16, 2020) CONCERT PHARMACEUTICALS, INC. 13,997 Shares of Series X1 Preferred Stock 2,253,000 Shares of Common Stock Warrants to Purchase up to 16,250 Shares of Series X1 Preferred Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offe |
|
| August 5, 2021 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results CTP-543 Phase 3 Program On Track to Support NDA Filing in Early |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCERT PHA |
|
| June 11, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 17, 2021 |
Exhibit 10.1 AMENDMENT TO ASSET PURCHASE AGREEMENT This AMENDMENT TO ASSET PURCHASE AGREEMENT (this ?Amendment?), dated as of May 17, 2021, to that certain Asset Purchase Agreement (as may be further amended or modified from time to time, the ?Agreement?), dated as of March 3, 2017, is entered into by and among Concert Pharmaceuticals, Inc. (?Seller?), Vertex Pharmaceuticals (Europe) Limited (?Buy |
|
| May 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 4, 2021 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine E. Koenigsberg (Investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports First Quarter 2021 Financial Results CTP-543 Phase 3 Program for Alopecia Areata Advancing as Plann |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCERT PH |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| February 25, 2021 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (Investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (Media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs CTP-543 Phase 3 Program Advancing in A |
|
| February 25, 2021 |
Summary of Non-Employee Director Compensation Program EX-10.12 2 q420exhibit1012.htm EX-10.12 Exhibit 10.12 Summary of Non-Employee Director Compensation Program The Board of Directors (the “Board”) of Concert Pharmaceuticals, Inc. (the “Company”) has approved the following non-employee director compensation program. Each non-employee director will receive a cash retainer for service on the Board and for service on each committee of which the directo |
|
| February 25, 2021 |
Subsidiaries of the Registrant EX-21.1 3 q420exhibit211.htm EX-21.1 Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Concert Pharmaceuticals Securities Corp. Massachusetts Concert Pharma U.K. Ltd United Kingdom Concert Pharma Ireland Limited Ireland |
|
| February 25, 2021 |
Power of Attorney (included on the signature pages of this Registration Statement) As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36310 CONCERT PHARMA |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 16, 2021 |
EX-99.1 2 d74809dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 20 |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022 105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CONCERT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Concert Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 206022105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 8, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* CONCERT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 206022105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| December 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 11, 2020 |
Exhibit 3.1 SECOND AMENDMENT TO AMENDED AND RESTATED BY-LAWS OF CONCERT PHARMACEUTICALS, INC. The Amended and Restated By-laws of Concert Pharmaceuticals, Inc., as amended, are hereby further amended by amending and restating Article V, Section 5.9 thereof in its entirety to read as follows: “5.9 Exclusive Jurisdiction of Delaware Courts or the Federal District Courts of the United States. Unless |
|
| November 12, 2020 |
November 12, 2020 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jeffrey Gabor Re: Concert Pharmaceuticals, Inc. Registration Statement on Form S-3 (No. 333-249862) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Concert Pharmaceuticals, Inc. hereby requests that the effective date of the above-referenc |
|
| November 5, 2020 |
EX-1.3 2 d33613dex13.htm EX-1.3 Exhibit 1.3 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM November 5, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment”) is entered into as of the date first written above by Concert Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Je |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCER |
|
| November 5, 2020 |
Form of Subordinated Indenture Exhibit 4.3 CONCERT PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES 1 CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) |
|
| November 5, 2020 |
EX-4.4 5 d33613dex44.htm EX-4.4 Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPO |
|
| November 5, 2020 |
EX-4.5 Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N |
|
| November 5, 2020 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update CTP-543 THRIVE-AA1 Phase 3 Trial Init |
|
| November 5, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on November 5, 2020 Registration No. |
|
| November 5, 2020 |
EX-4.2 Exhibit 4.2 CONCERT PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04 (c) 312(c) 4.04 (c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCERT PHA |
|
| August 6, 2020 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update CTP-543 Phase 3 Trial Initiation in |
|
| June 12, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 30, 2020 |
10-Q 1 q1202010-q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| April 30, 2020 |
EX-99.1 2 q120earningsrelease.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Updat |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| February 27, 2020 |
CNCE / Concert Pharmaceuticals, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36310 CONCERT PHARMA |
|
| February 27, 2020 |
EX-10.9 4 a2019exhibit109.htm EXHIBIT 10.9 Exhibit 10.9 [Date] [Name and Address] Dear [Name]: This agreement [revises/defines] the terms of your [continued] employment as of Concert Pharmaceuticals, Inc. (the “Company” or “Concert” and, with you, the “Parties”) reporting to the Company’s Chief Executive Officer, effective as of (the “Effective Date”). You agree to continue to perform the duties o |
|
| February 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-36310 20-4839882 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 27, 2020 |
EX-10.8 3 a2019exhibit108.htm EXHIBIT 10.8 Exhibit 10.8 May 16, 2018 Roger D. Tung c/o Concert Pharmaceuticals, Inc. 99 Hayden Avenue, Suite 500 Lexington, MA 02421 Dear Dr. Tung: This agreement revises the terms of your continued employment as President and Chief Executive Officer of Concert Pharmaceuticals, Inc. (the “Company” or “Concert” and, with you, the “Parties”) reporting directly to the |
|
| February 27, 2020 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Concert Pharmaceuticals Securities Corp. Massachusetts Concert Pharma U.K. Ltd United Kingdom Concert Pharma Ireland Limited Ireland |
|
| February 27, 2020 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (Investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (Media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports 2019 Financial Results and Provides Update on Clinical Programs CTP-543 Phase 3 Program for Treatment |
|
| February 27, 2020 |
Summary of Non-Employee Director Compensation Program EX-10.12 5 a2019exhibit1012.htm EXHIBIT 10.12 Exhibit 10.12 Summary of Non-Employee Director Compensation Program The Board of Directors (the “Board”) of Concert Pharmaceuticals, Inc. (the “Company”) has approved the following non-employee director compensation program. Each non-employee director will receive a cash retainer for service on the Board and for service on each committee of which the d |
|
| February 27, 2020 |
EX-4.4 2 a2019exhibit44.htm EXHIBIT 4.4 Exhibit 4.4 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Concert Pharmaceuticals, Inc. (“us,” “our,” “we” or the “Company”) is a summary of the rights of our common stock and certain provisions of our restated certificate of incorporation and our amended and restated by-laws currently in effect. This summary does not purport |
|
| February 27, 2020 |
Power of Attorney (included on the signature pages of this Registration Statement) As filed with the Securities and Exchange Commission on February 27, 2020 Registration No. |
|
| February 14, 2020 |
CNCE / Concert Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022 105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 14, 2020 |
CNCE / Concert Pharmaceuticals, Inc. / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2020 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2020 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 206022105 (CUSIP Nu |
|
| February 14, 2020 |
SC 13G/A 1 cnce-sc13ga123119.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CONCERT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 206022 105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Fil |
|
| February 14, 2020 |
CNCE / Concert Pharmaceuticals, Inc. / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* CONCERT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 206022105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2020 |
EX-99.1 2 ex991to13ga307422cnc021420.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the shares of Common Stock of Concert Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned purs |
|
| February 12, 2020 |
SC 13G 1 dfs147.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CONCERT PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 206022105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 6, 2020 |
CNCE / Concert Pharmaceuticals, Inc. / Arkin Moshe - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 206022105 (CUSIP Number) January 28, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| January 28, 2020 |
4,752,420 Shares Pre-Funded Warrants to Purchase 1,800,000 Shares of Common Stock Common Stock 424B5 1 d872832d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223334 PROSPECTUS SUPPLEMENT (to Prospectus dated March 7, 2018) 4,752,420 Shares Pre-Funded Warrants to Purchase 1,800,000 Shares of Common Stock Common Stock We are offering 4,752,420 shares of our common stock. We are also offering to a certain existing investor the opportunity to purchase, i |
|
| January 28, 2020 |
Shares Pre-Funded Warrants to Purchase Shares of Common Stock Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223334 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| January 28, 2020 |
Concert Pharmaceuticals Announces Pricing of Public Offering Exhibit 99.1 For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Announces Pricing of Public Offering Lexington, MA (January 28, 2020) – Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today |
|
| January 28, 2020 |
Exhibit 4.1 CONCERT PHARMACEUTICALS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: January [], 2020 Concert Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Perceptive Li |
|
| January 28, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2020 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Commiss |
|
| January 28, 2020 |
Exhibit 1.1 Execution Version 4,752,420 Shares Pre-Funded Warrants to Purchase 1,800,000 Shares Concert Pharmaceuticals, Inc. UNDERWRITING AGREEMENT January 28, 2020 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Concert Pharmaceuticals, Inc., a Delaware corporation (the “Company”), propo |
|
| January 22, 2020 |
8-K 1 form8-kpressrelease.htm 8-K CTP-543 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2020 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-36310 20-4839882 (State or oth |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCER |
|
| November 7, 2019 |
EX-99.1 2 q319earningsrelease.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Compa |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2019 Concert Pharmaceuticals, Inc. |
|
| October 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 23, 2019 Concert Pharmaceuticals, Inc. |
|
| September 5, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 5, 2019 Concert Pharmaceuticals, Inc. |
|
| September 5, 2019 |
ctp543phase2irpresentati CTP-543 Phase 2 Results in Patients with Moderate-to-Severe Alopecia Areata September 3, 2019 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| August 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2019 Concert Pharmaceuticals, Inc. |
|
| August 1, 2019 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update Conference Call Scheduled Today at 8 |
|
| August 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCERT PHA |
|
| July 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 206022105 (CUSIP Nu |
|
| June 17, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2019 Concert Pharmaceuticals, Inc. |
|
| May 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2019 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Commi |
|
| May 2, 2019 |
EX-99.1 2 q119earningsrelease.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports First Quarter 2019 Financial Results Conference Call Sc |
|
| May 2, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2019 Concert Pharmaceuticals, Inc. |
|
| May 2, 2019 |
10-Q 1 q1201910-q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| April 29, 2019 |
DEF 14A 1 a2019proxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 206022105 (CUSIP Nu |
|
| March 25, 2019 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, $0. |
|
| March 25, 2019 |
CNCE / Concert Pharmaceuticals, Inc. / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 1, 2019 |
Up to $50,000,000 Common Stock PROSPECTUS SUPPLEMENT (To Prospectus Dated March 7, 2018) Up to $50,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or sale agreement, with Jefferies LLC, or Jefferies, dated March 1, 2019, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. |
|
| March 1, 2019 |
OPEN MARKET SALE AGREEMENTSM March 1, 2019 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Concert Pharmaceuticals, Inc. |
|
| March 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2019 Concert Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36310 20-4839882 (State or other jurisdiction of incorporation) (Commis |
|
| February 28, 2019 |
CNCE / Concert Pharmaceuticals, Inc. S-8 As filed with the Securities and Exchange Commission on February 28, 2019 Registration No. |
|
| February 28, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 q418earningsrelease-8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2019 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36310 20-4839882 (State or Other Ju |
|
| February 28, 2019 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (Investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (Media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs Significant Clinical Progre |
|
| February 28, 2019 |
10-K 1 cnce201810-k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu |
|
| February 28, 2019 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Concert Pharmaceuticals Securities Corporation Massachusetts Concert Pharma U.K. Ltd United Kingdom Concert Pharma Ireland Limited Ireland |
|
| February 28, 2019 |
Summary of Director Compensation Program Exhibit 10.22 SUMMARY OF DIRECTOR COMPENSATION PROGRAM The board of directors (the “Board”) of Concert Pharmaceuticals, Inc. (the “Company”) has approved the following director compensation program. Under this director compensation program, the Company will pay its non-employee directors retainers in cash. Each non-employee director will receive a cash retainer for service on the Board and for ser |
|
| February 14, 2019 |
CNCE / Concert Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022 105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 206022105 (CUSIP Nu |
|
| February 7, 2019 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 7, 2019 with respect to the common stock, par value $0.001 per share, of Concert Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions |
|
| February 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 206022105 (CUSIP Num |
|
| December 17, 2018 |
8-K 1 a8-kmegfitgeraldresignation.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2018 Concert Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36310 20-4839882 (State or Othe |
|
| November 23, 2018 |
CNCE / Concert Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Concert Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 206022 105 (CUSIP Number) November 12, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| November 1, 2018 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update Conference Call Scheduled Today at 8: |
|
| November 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2018 Concert Pharmaceuticals, Inc. |
|
| November 1, 2018 |
CNCE / Concert Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCER |
|
| August 2, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2018 Concert Pharmaceuticals, Inc. |
|
| August 2, 2018 |
EX-99.1 2 q218earningsrelease.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (914) 204-6412 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Comp |
|
| August 2, 2018 |
CNCE / Concert Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCERT PHA |
|
| June 18, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2018 Concert Pharmaceuticals, Inc. |
|
| May 3, 2018 |
CNCE / Concert Pharmaceuticals, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| May 3, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2018 Concert Pharmaceuticals, Inc. |
|
| May 3, 2018 |
Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (845) 635-9828 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports First Quarter 2018 Financial Results Conference Call Scheduled Today at 8:30 a.m. EDT Lexington, MA (M |
|
| May 3, 2018 |
CNCE / Concert Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36310 CONCERT PH |
|
| April 10, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2018 Concert Pharmaceuticals, Inc. |
|
| March 22, 2018 |
HUWX / Heatwurx Inc. / Concert Pharmaceuticals, Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Processa Pharmaceuticals, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 74275C106 (CUSIP Number) March 19, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| March 7, 2018 |
CNCE / Concert Pharmaceuticals, Inc. CORRESP CORRESP March 7, 2018 VIA EDGAR Securities and Exchange Commission 100 F Street, N. |
|
| March 1, 2018 |
CNCE / Concert Pharmaceuticals, Inc. S-8 Document As filed with the Securities and Exchange Commission on March 1, 2018 Registration No. |
|
| March 1, 2018 |
CNCE / Concert Pharmaceuticals, Inc. S-3 S-3 1 a2018s-3filing.htm S-3 As filed with the Securities and Exchange Commission on March 1, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONCERT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-4839882 (State or other jurisdiction of incor |
|
| March 1, 2018 |
Exhibit Exhibit 4.1 CONCERT PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) |
|
| March 1, 2018 |
Form of Subordinated Indenture EX-4.2 3 exhibit42-formofsubordinat.htm EXHIBIT 4.2 Exhibit 4.2 CONCERT PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES 1 CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313 |
|
| March 1, 2018 |
Exhibit Exhibit 99.1 NEWS RELEASE For additional information contact: Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc. (781) 674-5284 [email protected] Kathryn Morris (media) The Yates Network (845) 635-9828 [email protected] FOR IMMEDIATE RELEASE Concert Pharmaceuticals Reports Year Ended 2017 Financial Results CTP-543 On Track to Report Topline Phase 2a Results in Alope |
|
| March 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2018 Concert Pharmaceuticals, Inc. |
|
| March 1, 2018 |
EX-4.3 4 exhibit43-formofseniornote.htm EXHIBIT 4.3 Exhibit 4.3 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DE |
|
| March 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36310 CONCERT PHARM |
